Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patients

26 Aug 2023

Abstract excerpt

Immune checkpoint inhibitors (ICIs), including antibodies targeting anti-cytotoxic T lymphocyte antigen 4 (CTLA-4), anti-programmed cell death 1 (PD-1), anti-programmed cell death 1 ligand 1 (PD-L1) have revolutionized cancer treatment.1, 2 Both PD-1 and CTLA-4 are upregulated upon T-cell activation and function to inhibit peripheral T-cell responses. These receptors maintain immune homeostasis, limiting tissue...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37632320
DOI: 10.1111/imr.13270

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The evolving landscape of immune‐related adverse events that follow immune checkpoint immunotherapy in cancer patientsPMID 37632320Read ↗

Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint InhibitorsSemantic proximity Read ↗

Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint BlockadeSemantic proximity Read ↗

Research progress on mechanisms and predictive biomarkers for immune-related adverse eventsSemantic proximity Read ↗

Assessing the Pharmacological and Pharmacogenomic Data of PD-1/PD-L1 Inhibitors to Enhance Cancer Immunotherapy Outcomes in the Clinical SettingSemantic proximity Read ↗

Tumor immune checkpoints and their associated inhibitorsSemantic proximity Read ↗

Adverse events induced by immune checkpoint inhibitors.Semantic proximity Read ↗

Thyroid-related Adverse Events Caused by Immune Checkpoint Inhibitors Associated with Therapeutic Outcomes in Cancer Patients: a systematic review and meta-analysisSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Targeting the PD-1/PD-L1 Signaling Pathway for Cancer Therapy: Focus on BiomarkersSemantic proximity Read ↗

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer TherapeuticsSemantic proximity Read ↗

Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: a multi-institutional cohort studySemantic proximity Read ↗

Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.